Dienogest per os (Oral Dienogest)
Dienogest 2 mg daily is the definitive medical treatment for endometriosis-associated pain, demonstrating superior efficacy to combined oral contraceptives and comparable effectiveness to GnRH agonists, with better tolerability for long-term use.
Primary Indication: Endometriosis
Dienogest is specifically indicated for treating endometriosis-associated pain, including dysmenorrhea, dyspareunia, dyschezia, and chronic pelvic pain 1, 2. This fourth-generation progestin works through multiple mechanisms:
- Moderate estrogen suppression without complete ovarian shutdown
- Anti-inflammatory effects on endometriotic lesions
- Regulation of nerve growth factor to reduce pain sensitization
- Direct anti-proliferative effects on endometrial tissue 2
Dosing for Endometriosis
Standard dose: 2 mg once daily, taken continuously without hormone-free intervals 1. This can be initiated:
- After surgical confirmation of endometriosis
- As empirical treatment based on clinical diagnosis alone 3
- Post-operatively to prevent recurrence 4
Efficacy Evidence
The most recent meta-analysis demonstrates dienogest significantly outperforms combined oral contraceptives for dysmenorrhea control in deep infiltrating endometriosis 4. When compared to GnRH agonists (leuprorelin, buserelin, triptorelin), dienogest shows non-inferior pain reduction but with substantially fewer hypoestrogenic side effects 1.
Long-term data extending to 108 months shows progressive improvement in endometrioma size (from 33.2 mm to 7 mm) and sustained pain relief, with benefits increasing with treatment duration 5.
Secondary Use: Combined Oral Contraceptives
Dienogest 2 mg combined with ethinylestradiol 30 mcg serves as a reliable contraceptive with additional benefits 6:
- Contraceptive efficacy comparable to other COCs
- Cycle control with reduced menstrual bleeding intensity and duration
- Antiandrogenic effects: improves acne vulgaris, reduces hair and skin greasiness
- Treatment of heavy menstrual bleeding 7
This formulation is dosed as one tablet daily for 21 days followed by 7 hormone-free days (standard COC regimen).
Contraindications
While the provided FDA labels 8 appear to be mislabeled (describing topical antifungal use), standard progestin contraindications apply based on clinical knowledge:
- Active or history of thromboembolic disease
- Known or suspected breast cancer or hormone-sensitive malignancies
- Undiagnosed abnormal uterine bleeding
- Severe hepatic disease
- Pregnancy
Monitoring Recommendations
Bone Health Surveillance
Critical caveat: Long-term dienogest use (>15 months) is associated with osteopenia in 27.6% of patients 5.
Monitoring protocol:
- Baseline bone mineral density (BMD) assessment before initiating therapy
- Repeat BMD every 24 months during continued treatment 5
- Consider calcium and vitamin D supplementation
Common Side Effects Requiring Monitoring
Most frequent (decreasing over time):
- Abnormal menstrual bleeding patterns (22.9%) - generally well-tolerated, rarely leads to discontinuation 5, 1
- Headaches
- Weight gain
- Reduced libido
- Breast tenderness
- Nausea/vomiting 6
Important distinction: These side effects are significantly less severe than the hypoestrogenic effects seen with GnRH agonists (hot flashes, vaginal dryness, severe bone loss) 1, 9.
Clinical Follow-up
- Initial assessment at 3 months to evaluate pain response and tolerability
- Ongoing evaluation every 6-12 months for symptom control and side effects
- Pain assessment using VAS scores for dysmenorrhea, dyspareunia, and dyschezia
- Ultrasound monitoring of endometriomas if present (expect progressive size reduction) 5
Treatment Algorithm
For endometriosis-associated pain:
- First-line: Dienogest 2 mg daily monotherapy (preferred over COCs based on superior efficacy) 4
- Alternative: Ethinylestradiol/dienogest COC if contraception is also desired
- Refractory cases: Consider GnRH antagonists (elagolix, relugolix, linzagolix) for rapid control, though dienogest remains better for long-term management 9
For contraception with additional benefits (acne, heavy bleeding):
- Ethinylestradiol 30 mcg/dienogest 2 mg combination 6
Long-term Safety Profile
Dienogest demonstrates excellent long-term tolerability with sustained efficacy beyond 5 years 10, 5. Unlike GnRH agonists that require add-back therapy to prevent bone loss 3, dienogest's moderate estrogen suppression allows for extended use, though BMD monitoring remains essential 5.
Fertility after discontinuation: Small delay in conception during first 3 cycles, but no long-term impairment regardless of treatment duration 6.